Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 447 clinical trials
Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy (ANGIOSAFE2)

Experimental data suggest that GLP-1 promote endothelial cell growth and angiogenesis which may have beneficial effects on the cardiovascular system but harmful effects on the retina . This

incretins
hypoglycemic agents
retinopathy
glucagon-like peptide 1
antidiabetic agents
  • 0 views
  • 23 Feb, 2022
  • 1 location
Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Diabetic retinopathy (DR) is an important cause of blindness.

diabetic retinopathy
glycosylated hemoglobin
type 2 diabetes mellitus
insulin
blindness
  • 28 views
  • 21 Jan, 2021
Effectiveness of Periocular Drug Injection in CATaract Surgery

Cystoid macular edema (CME) is a major cause of suboptimal postoperative visual acuity after cataract surgery. Topical steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent CME. However, noncompliance with eye drops may compromise the effectiveness of treatment. Dropless periocular drug delivery during cataract surgery may improve the outcomes …

ketorolac
macular edema
triamcinolone
phacoemulsification
dexamethasone
  • 0 views
  • 23 Dec, 2021
  • 5 locations
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy (CANBERRA)

The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to

diabetic retinopathy
proliferative diabetic retinopathy
glycosylated hemoglobin
background diabetic retinopathy
type 2 diabetes mellitus
  • 91 views
  • 17 Jun, 2022
  • 63 locations
Fenofibrate for Prevention of DR Worsening (Protocol AF)

proliferative diabetic retinopathy (PDR) or and the results are adopted by the community of retina specialists, a new strategy to prevent vision threatening complications of diabetes could be widely adopted

diabetes
severe nonproliferative diabetic retinopathy
microaneurysms
insulin
pupil dilation
  • 8 views
  • 15 May, 2022
  • 39 locations
Bangladesh PRODUCTIVity in Eyecare Trial (B-PRODUCTIVE)

productivity of retina specialists in Bangladesh. Globally, the number of people with diabetes mellitus is increasing. Diabetic retinopathy is a chronic, progressive complication of diabetes mellitus

macular edema
corrected visual acuity
visual loss
Accepts healthy volunteers
blindness
  • 0 views
  • 16 May, 2022
  • 1 location
A Trial on Ophthalmologist-delivered Health Education on Top of Routine Community Care

Diabetic retinopathy affects over one third of all people with diabetes and is one of the leading causes of vision loss. The management of diabetes and its complications should include screening

  • 0 views
  • 22 Mar, 2022
  • 1 location
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN)

PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized, controlled study evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT) injection in pediatric subjects (<8 years of age) with LCA10 due to the c.2991+1655A>G mutation over 24 months of treatment.

  • 0 views
  • 07 Apr, 2022
  • 3 locations
Village-Integrated Eye Worker Trial II (VIEW II)

treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Loss of vision from these

diabetic retinopathy
visual loss
visual impairment
age-related macular degeneration
blindness
  • 42 views
  • 10 Feb, 2022
  • 1 location
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI)

Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3. As from Month 3, in about half of the subjects, the effect …

macular edema
growth factor
spectral domain optical coherence tomography
type 2 diabetes mellitus
aflibercept
  • 20 views
  • 18 Jun, 2022
  • 55 locations